3073 Exploratory analysis of frontline therapies in REVEL: A randomized phase III study of ramucirumab (RAM) plus docetaxel (DOC) versus DOC for the treatment of stage IV non-small-cell lung cancer (NSCLC) after disease progression on platinum-based therapy. (September 2015) - Garon, E.B.; Scagliotti, G.V.; Gautschi, O.; Reck, M.; Thomas, M.; Docampo, L.I.; Kalofonos, H.; Kim, J.H.; Gans, S.; Brustugun, O.T.; Orlov, S.V.; Ferry, D.; et al.